GLP1 ‐ 1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta‐analysis of randomised controlled trials and cohort studies
Pooled result · Walking distance (2 RCTs, n = 847)Result — go to the resultHazard ratio 1.10 95% CI 1.05–1.15Authors' conclusion
This meta-analysis suggests that GLP-1RAs are associated with a significant improvement in functional walking distance and a reduction in the risk of LEA in people with type 2 and PAD. Further dedicated RCTs are needed to confirm these limb-specific benefits of GLP-1RAs.
Study context
- Population
- Adults with T2D and peripheral artery disease (PAD)
- Participants
- 107,092 adults3 randomised controlled trials (RCTs)4 cohorts
- Comparison
- GLP-1 RAs vs placebo or other glucose-lowering drugs
- Outcome
- Walking distance, major adverse limb events (MALE) or lower extremity amputation (LEA)
Methodological detailsrandom-effects model, RoB2 and ROBINS-I risk of bias, GRADE certainty, Databases searched up to 10 October 2025
- Random-effects model
- RoB2 and ROBINS-I risk of bias
- GRADE certainty
- Databases searched up to 10 October 2025
Pooled result
Walking distance (2 RCTs, n = 847)
Hazard ratio
1.10
95% CI 1.05–1.15
P < 0.001
Liraglutide or semaglutidevs Placebo or other glucose-lowering drugs
HR 1.10 (95% CI 1.05–1.15); P < 0.001
As reported in the abstract
Further pooled results
Lower extremity amputation (LEA) by GLP-1 RA therapy (subgroup analyses)
- Significant difference between GLP-1 RA therapies
- P < 0.001
- LEA risk reduction, tirzepatide
- 55%
- LEA risk reduction, semaglutide
- 54%
- No difference in LEA outcome excluding patients with T2D and DFU at baseline
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
GLP1 ‐ 1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta‐analysis of randomised controlled trials and cohort studies. Diabetes Obes Metab. Published 8 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →